Podcasts about astex

In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Gandara 0:19 •    The interview 1:02 •    Can you tell me a little more about what you are working on now? 1:25 •    How did you get engaged with the community in Hawaii?  6:30 •    What do you think is going to happen with ctDNA moving forward? 8:29 •    Can you utilize ctDNA and minimal residual disease information to determine how long patients need to be on adjuvant therapy?  11:42 •    How did you get into the ctDNA space?  15:06 •    How do you see AI transforming health care beyond providing patients with more information and taking more ownership of their health?  18:28 •    Can you tell us more about how a second opinion clinic works? How did this type of clinic develop and become part of what you do?  23:17 •    What are some of your predictions as to what will happen in oncology care over the next ten to twenty years?  29:00 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 37:30 •    How to contact Gandara 38:47 •    Thanks for listening 39:10 David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug development and biomarker development. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email drgandara@ucdavis.edu.  Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine. 

Artificial intelligence is touching all aspects of drug development with a lot of focus, and potential noise, on the early stages of drug discovery. In this episode of Bloomberg Intelligence's Vanguards of Health podcast BI's Head of Global Industries Sam Fazeli discusses the contributions of machine learning, AI and AlphaFold 3 in drug discovery with Harren Jhoti, cofounder of Astex in 1999. Jhoti remains CEO of the group as part of Otsuka Pharmaceuticals. Astex's pioneering work in fragment-based drug discovery has lead to three marketed oncology drugs, including Novartis' Kisqali used for breast cancer. We delve into the steps in which AI can have meaningful impact and what this may mean for saving time in drug development and reducing the risk of drug failure.See omnystudio.com/listener for privacy information.

Nacho Travesí Barrera es un joven de origen español, muy inquieto y creativo. Él estudió ciencias económicas en la Universidad Autónoma de Madrid, es licenciado en derecho de la Universidad Complutense de Madrid y realizó un programa de alta dirección y marketing en el Esade de España. Entre 2011 y 2013 formó parte de ASTEX, compañía especializada en formación de idiomas para empresas y asesoramiento de estudios en el extranjero. En 2012 fue CEO y business developer Shouton Sl, emprendimiento de sastrería a medida a domicilio.Entre 2012 y 2014 Nacho también fue Regional Sales and Business Development de Education First. Luego, entre 2014 y 2016 fue Sales Director & Country Manager para España de beWanted, empresa de búsqueda de talento. Entre 2016 y 2019 formó parte de Gympass como Head de Corporate Sales B2B para España y Francia.Nacho es también seed investor en múltiples startups, como Fence, Quench, Invopop. Vualapp, , entre otras. Y finalmente, en 2019 se incorpora a Cobee como Co-Founder y CSO.Recuerda que ahora puedes escuchar Cuentos Corporativos en vivo. Estamos en RADIOMEX los martes y jueves a las 8 pm de la CDMX.Síguenos en:www.cuentoscorporativos.com Newsletter. Escribe una ReseñaEncuesta Audiencia Nuestras redes sociales:Facebook Instagram. LinkedinTwitter Hosted on Acast. See acast.com/privacy for more information.

See the full story with pictures at: https://www.otsuka.co.jp/company/global-topics/2018/20180125_vol102.html On January 25, the BioIndustry Association (BIA) honoured Dr. Harren Jhoti, president & CEO of Astex, UK (an independent subsidiary of Otsuka Pharmaceutical) with a Lifetime Achievement Award. The Award was presented by Dr. Jane Osbourn (BIA Chair) at a dinner attended by 700 professionals from the UK life sciences sector. Dr. Osbourne commented, “Harren’s contribution to the UK biotech sector recognises his combination of scientific and leadership skills, as well as his passion and determination to succeed. [...] He makes an active contribution to initiatives in the UK biotech sector and provides a role-model for today’s entrepreneurs.” On receiving the award Dr. Jhoti paid tribute to the three scientist-entrepreneurs with whom he co-founded Astex in 1999, and to his team, saying, “As scientists we always hope that our discoveries will make a difference and as entrepreneurs we strive to build sustainable companies to translate those discoveries into significant new medicines for patients. At Astex we have been lucky enough to achieve both of these goals due largely to our highly talented team.” Dr. Jhoti also commented how Astex is now thriving as an independent subsidiary of the Otsuka group of companies. At Astex, Dr. Jhoti and his current and former colleagues have made pathbreaking progress in fragment-based drug discovery, which identifies and assembles small chemical fragments to produce drug leads with strong binding affinity to biological targets. To date, one such lead has been pursued by a drug maker all the way through to regulatory approval in the US and EU for use in patients with a type of advanced breast cancer. The BIA is the trade association for innovative enterprises involved in UK bioscience and the Lifetime Achievement Award is the highest accolade given by the BIA.

https://www.otsuka.co.jp/en/company/globalnews/detail.php?id=238&date=2017-03-07 Every year since 2000, Astex employees and their families have taken part in the Light The Night of East Bay event in Walnut Creek in Northern California to raise much needed funds and awareness to support the Leukemia and Lymphoma Society (LLS). The LLS, founded in 1949, is the largest voluntary organization in the US dedicated to research, finding cures and ensuring access to treatment for blood cancer patients. In 1964 the survival rate for childhood leukemia was just 3%, now thanks in part to research, funding, and better support for patients from the society the survival rate is 91%. Since its inception, the society has contributed over $1billion towards improving the lives and outcomes for blood cancer patients. Light The Night draws nearly one million participants over the year to join one of LLS’s 160+ evening events across the US. Participants walk the course holding illuminated lanterns in three colours: white lanterns are carried by patients and survivors; red lanterns by supporters; gold by participants who are walking in memory of a loved one. In speaking about Light The Night, the East Bay Campaign Director for LLS, Andrea Orozco said, “When LLS walks, cancer runs”. Last year, Astex employees raised $44,393 for LLS through fund raising events and the Astex corporate match program. 57 employees from Team Astex and their family members joined the event to raise awareness for blood cancers. To date, Astex and its employees have contributed in excess of $465,000 to LLS activities such as Light The Night, Patient Assistance Programs, and educational events and grants. In addition, an Astex employee has served on the local board or was a member of the LLS organizing committee for the past 15 years. In recognition of their efforts, executives and staff members of Astex received awards from the society, including one for being the top corporate fundraising team and one for the most money raised by an individual. To Astex these activities are more than about raising money for the society, as the President and Chief Medical Officer of Astex, Mohammad Azab explains, “Every employee at Astex is deeply committed to the search for a cure to blood cancers and we are proud to support the mission of the LLS in improving the lives of patients and their families”. Otsuka affiliate Astex is a leader in innovative drug discovery and development. The company is committed to the fight against cancer as well as disorders of the central nervous system. Find out more about Astex at www.astx.com

Sobre o episódio Micros clássicos não são apenas jogos, mas também trabalho duro. Por isso fizemos a série O office antes do Office. E começamos com os processadores de texto. Nesta parte do episódio Depois de passear por metralhadoras, máquinas de escrever, esferas e margaridas, falamos de Wordstar, WordPerfect, Electric Pencil, Tasword e ASTEX. Ficha … Continue lendo Episódio 56 – O office antes do Office: Processadores de texto – Parte A →

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord: